Pharmacokinetic/pharmacodynamic evaluation of a novel potassium channel opener, SKP-450, in healthy volunteers

Journal of Clinical Pharmacology

Volumn 40, Issue 7, 2000, Pages 752-761

  Jang, I J ^a,b   Yu, K S ^a,b   Shon, J H ^c   Bae, K S ^a,b   Cho, J Y ^a   Yi, S Y ^a   Shin, S G ^a,b   Ryu, Keun Ho ^d   Cho, Y B ^d   Kim, D K ^d   Yoo, S E ^e  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Inje University College of Medicine   (South Korea)

^d SK Chemicals   (South Korea)

^e Korea Research Institute of Chemical Technology   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

2 (1,3 DIOXOLAN 2 YL) 2 METHYL 6 NITRO 4 (2 OXO 1 PYRROLIDINYL) 2H 1 BENZOPYRAN; BIMAKALIM; CROMAKALIM; DRUG METABOLITE; NICORANDIL; PINACIDIL; PLACEBO; POTASSIUM CHANNEL; POTASSIUM CHANNEL STIMULATING AGENT; SKP 310; SKP 818; UNCLASSIFIED DRUG;

ADULT; ALDOSTERONE BLOOD LEVEL; ANTIHYPERTENSIVE ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CARDIOGRAPHY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG SCREENING; DRUG STRUCTURE; EGG; FOOD DRUG INTERACTION; FOOD INTAKE; HUMAN; MEASUREMENT; MILK; PLASMA RENIN ACTIVITY; TACHYCARDIA; VASODILATATION;

EID: 0033638417     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700022009512     Document Type: Article

References (22)

1. Potent hemodynamic effects of bimakalim, a new potassium channel opener, in humans
2. Cromakalim, nicorandil and pinacidil: Novel drugs which open potassium channels in smooth muscle
3. Potassium channels as pharmacological targets in cardiovascular medicine
4. Pharmacokinetics and safety of a novel, long-acting, prodrug-type potassium channel opener, Y-27152, in healthy volunteers
5. Haemodynamic and clinical effects of an intravenous potassium channel opener - A review
6. Clinical studies with the potassium channel activator cromakalim in normotensive and hypertensive subjects
7. + channel
8. + channel opener, in comparison with levcromakalim
9. Antihypertensive effects of the novel potassium channel activator SKP-450 and its major metabolites in rats
10. Cardiovascular pharmacology of SKP-450, a new potassium channel activator, and its major metabolites SKP-818 and SKP-310
11. Hemodynamic profile of SKP-450, a new potassium-channel activator
12. +(ATP) opener, and its major metabolite KR-30818 on isolated rat hearts
13. Disposition and metabolism of 2-(2'(1',3'-dioxolan-2-yl)-2- methyl-4-(2'-oxopyrrolidin-1-Yl)-6-nitro-2h-1-benzopyran (SKP-450) in rats
14. Microbore high-performance liquid chromatographic determination of cisapride in rat serum samples using column switching
15. Impedance cardiography for cardiac output measurement: An evaluation of accuracy and limitations
16. Application of noninvasive techniques for measuring cardiac output in hypertensive patients
17. Antihypertensive effect of cardiovascular Ca2+-antagonist in hypertensive patients in the absence and presence of beta-adrenergic blockade
18. Effect of diltiazem, a calcium antagonist, on renin secretion from rat kidney slices
19. Multiple oral doses of nicardipine, a calcium-entry blocker: Effects on renal function, plasma renin activity, and aldosterone concentration in mild-to-moderate essential hypertension
20. Acute effects of the calcium antagonist, nifedipine, on blood pressure, pulse rate, and the renin-angiotensin-aldosterone system in patients with essential hypertension
21. Clinical pharmacokinetics of pinacidil, a potassium channel opener, in hypertension
22. Clinical pharmacology of potassium channel openers